Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 08:30 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of...
May 07, 2026 08:30 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy,...
April 15, 2026 09:00 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...